source
- Merck and Moderna report positive late-stage melanoma vaccine results, adding to 2026 cancer breakthrough yearMerck and Moderna announced that their personalized mRNA neoantigen vaccine achieved positive outcomes in a late-stage trial for melanoma patients. The data suggest the vaccine can stimulate an imm…
- FDA approves Ultragenyx gene therapy and Regeneron ultra-rare disease drugThe Food and Drug Administration gave the green light to a gene‑therapy product from Ultragenyx, marking a new treatment option in the company’s pipeline. In a separate decision, Regeneron secured…